Protagenic Therapeutics ( (PTIX) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Protagenic Therapeutics, Inc. has filed a Form 12b-25, notifying investors of a delay in its Form 10-Q (Quarter Report) for the quarter ended December 31, 2025. The company, formerly known as Atrinsic, Inc., remains based in New York and confirms it is otherwise current with its SEC filing obligations.
The sole reason given for the delay is that Protagenic cannot complete its Form 10-Q (Quarter Report) by the deadline without what it calls unreasonable effort or expense. The company refers to “remaining items” that still need to be finished but does not cite auditor changes, internal control failures, or any outside reviews as the cause.
While Protagenic initially checked the box indicating reliance on the standard short extension under SEC rules, it explicitly warns that it does not expect to file its Form 10-Q (Quarter Report) within the usual five-day grace period. This means investors may face a longer-than-normal information gap regarding the company’s most recent quarterly performance.
Management states that it does not anticipate any significant change in results of operations compared with the same quarter a year earlier. The company does not provide preliminary financial figures or guidance, and any expectations about its future filings and timing should be viewed as forward-looking statements that could change.
Protagenic emphasizes that it is working to complete the outstanding work on the delayed Form 10-Q (Quarter Report) as promptly as practicable. The notification is signed on behalf of the company by Chief Financial Officer Alexander K. Arrow, underscoring management’s responsibility for compliance and ongoing communication with shareholders.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Average Trading Volume: 97,152
Technical Sentiment Signal: Sell
Current Market Cap: $771.2K
Find detailed analytics on PTIX stock on TipRanks’ Stock Analysis page.